Cellectar Biosciences
CLRB
41 hedge funds and large institutions have $4.38M invested in Cellectar Biosciences in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
8% more funds holding
Funds holding: 38 → 41 (+3)
1.19% less ownership
Funds ownership: 11.98% → 10.8% (-1.2%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
36% less capital inflows, than outflows
Capital inflows: $1.23M | Capital outflows: $1.93M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$720K |
| 2 |
Worth Venture Partners
Fort Lee,
New Jersey
|
+$165K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$132K |
| 4 |
Two Sigma Advisers
New York
|
+$46.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$40.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boxer Capital
San Diego,
California
|
-$851K |
| 2 |
Maven Securities
St Helier,
Jersey
|
-$491K |
| 3 |
Renaissance Technologies
New York
|
-$262K |
| 4 |
Morgan Stanley
New York
|
-$242K |
| 5 |
Quilter Plc
London,
United Kingdom
|
-$16K |
CLRB Hedge Fund Activity: Q4 2021 in Review
41 of the 6,522 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2021, worth a combined $4.38M — down 35% from $6.77M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CLRB positions and 6 closed out — a net gain of 3 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $720K. The largest seller was Boxer Capital, exiting entirely with an estimated $851K sold.
- 41 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2021, up from 38 in Q3 2021.
- Funds reported $4.38M of Cellectar Biosciences stock for Q4 2021, down 35% quarter-over-quarter.
- 9 funds opened new Cellectar Biosciences positions in Q4 2021 and 6 closed out, a net change of +3 holders.
- The largest Cellectar Biosciences buyer in Q4 2021 was AIGH Capital Management, an estimated $720K added.
- The largest Cellectar Biosciences seller in Q4 2021 was Boxer Capital, an estimated $851K sold.
Based on aggregated 13F filings for Q4 2021.